The global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2023 and is expected to exhibit a CAGR of 14.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
PD-1 and PD-L1 inhibitors are monoclonal antibodies that target PD-1 and PD-L1, respectively. These antibodies help boost the immune system’s ability to fight cancer by blocking proteins that help tumors evade detection by the immune system. They have shown superior efficacy compared to chemotherapy in various cancer types like non-small cell lung cancer (NSCLC) and melanoma.
Market key trends:
One of the key trends in the PD-1 and PD-L1 inhibitor market is the rise in artificial intelligence applications. AI is helping accelerate drug discovery and development process in oncology. Companies are using AI and machine learning to analyze large patient datasets to better understand tumor characteristics and identify biomarkers that can predict response to immunotherapies. AI is also aiding in the discovery of new drug targets. This is expected to significantly reduce costs and time required for drug development.
The global PD-1 and PD-L1 inhibitor market is segmented based on type, application and end user. Based on type, it is divided into PD-1 inhibitor and PD-L1 inhibitor. Currently, PD-1 inhibitors dominate the market and accounts for the largest revenue share. PD-1 inhibitors are preferred over PD-L1 inhibitors as they offer superior efficacy and improved overall survival.
The global PD-1 And PD-L1 Inhibitor Market Share is expected to witness high growth, exhibiting CAGR of 14.% over the forecast period, due to increasing prevalence of cancer globally. The market size for 2023 is US$ 39.83 Bn.
North America dominates the global PD-1 and PD-L1 inhibitor market and is expected to continue its dominating position over the forecast period. This is attributed to increasing adoption of novel immunotherapies for cancer treatment and presence of highly developed healthcare infrastructure in the region. Asia Pacific exhibits the fastest growth over the forecast period owing to rising cancer incidence, growing healthcare spending and increasing healthcare awareness.
Key players operating in the PD-1 and PD-L1 inhibitor market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc. These players are focusing on new product launches, collaborations and regulatory approvals to strengthen their market position.